

Refine Search

Search Results -

Terms	Documents
L7 and (adding sulphhydryl residues)	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Saturday, December 17, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L9</u>	L7 and (adding sulphhydryl residues)	1	<u>L9</u>
<u>L8</u>	L7 and (modified PAI-1)	2	<u>L8</u>
<u>L7</u>	5679350.pn.	2	<u>L7</u>
DB=USPT; PLUR=YES; OP=OR			
<u>L6</u>	(PAI-1 same sulphhydryl)	2	<u>L6</u>
<u>L5</u>	L1 and (contains sulphhydryl group)	1	<u>L5</u>
<u>L4</u>	L3 and (cysteine or methionine)	1	<u>L4</u>
<u>L3</u>	L2 and (sulphhydryl group)	1	<u>L3</u>
<u>L2</u>	L1 and PAI-1	1	<u>L2</u>
<u>L1</u>	6303338.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
L11 and sulfhydryl	3

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, December 17, 2005 [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L12</u>	L11 and sulfhydryl	3	<u>L12</u>
<u>L11</u>	swiercz.in.	19	<u>L11</u>
<u>L10</u>	chorostowska-wynimko.in.	2	<u>L10</u>
<u>L9</u>	L7 and (adding sulfhydryl residues)	1	<u>L9</u>
<u>L8</u>	L7 and (modified PAI-1)	2	<u>L8</u>
<u>L7</u>	5679350.pn.	2	<u>L7</u>
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L6</u>	(PAI-1 same sulfhydryl)	2	<u>L6</u>
<u>L5</u>	L1 and (contains sulfhydryl group)	1	<u>L5</u>
<u>L4</u>	L3 and (cysteine or methionine)	1	<u>L4</u>
<u>L3</u>	L2 and (sulfhydryl group)	1	<u>L3</u>
<u>L2</u>	L1 and PAI-1	1	<u>L2</u>
<u>L1</u>	6303338.pn.	1	<u>L1</u>

END OF SEARCH HISTORY



The "AND" operator is unnecessary – we include all search terms by default. [\[details\]](#)

Web

Results 1 - 10 of about 316 for **PAI-1 and sulphhydryl group**. (0.25 seconds)

Reduced cardiac expression of plasminogen activator inhibitor 1 ...

Conclusion: These results suggest that perindopril reduces cardiac PAI-1 and ...
or without a **sulphhydryl group**: bradykinin may improve insulin resistance in ...
heart.bmjjournals.com/cgi/content/full/91/1/80 - [Similar pages](#)

[PDF] The Role of the Thiol Group in the Antithrombotic Action of Captopril

File Format: PDF/Adobe Acrobat - [View as HTML](#)
involvement of the **sulphhydryl group** in the antithrombotic effect of ...
Increased PAI-1 Ag levels, accompanied by no difference observed ...
www.schattauer.de/zs/thromb/2000/11/pdf/letters.pdf - [Similar pages](#)

Nutrition Journal | Full text | Homocysteine and reactive oxygen ...

R = any organic compound in the plasma with a thiol group (-SH) accessible ...
Cross linking or vulcanization of **sulphhydryl** rich proteins (leading to stiff ...
www.nutritionj.com/content/3/1/4 - 245k - [Cached](#) - [Similar pages](#)

[PDF] Statin Drugs and Dietary Isoprenoids Downregulate Protein ...

File Format: PDF/Adobe Acrobat - [View as HTML](#)
and conjugate to proteins via cystine **sulphhydryl** groups, located near the carboxy termini of ... downregulate the enzyme inhibitor, PAI1, which inhibits the ...
www.protein.bio.msu.ru/biokhimiya/contents/v67/pdf/bcm_0085.pdf - [Similar pages](#)

Full Article

In the absence of PAI-1, tPA activates plasminogen to generate plasmin. ...
Because of their **sulphhydryl** linkages, prenylated conjugates are subject to ...
www.protein.bio.msu.ru/biokhimiya/contents/v67/full/67010099.html - 28k - [Cached](#) - [Similar pages](#)

Angiogenesis and Cancer Control: From Concept to Therapeutic Trial

(PAI-1). Trace Elements, Copper, Zinc, Oncogenes, c-myc ... (3) contains a **sulphhydryl group** that converts plasminogen to angiostatin, ...
www.moffitt.usf.edu/pubs/ccj/v6n5/article2.htm - 202k - [Cached](#) - [Similar pages](#)

Abstracts (2004)

Binding of monoclonal antibody MA-55F4C12 to PAI-1 induced a decrease in k(lim) and K(0.5) at any pH but did not affect either the pKa of the **group** or an ...
pharm.kuleuven.be/biotech/abstract14.htm - 38k - [Cached](#) - [Similar pages](#)

Protective Effects of Angiotensin II Interruption

... MMP = matrix metalloproteinase; PAI-1 = platelet activator inhibitor-1; ...
This **sulphhydryl group** is thought to be responsible for many of the ...
www.medscape.com/viewarticle/515319_print - 94k - [Cached](#) - [Similar pages](#)

JBC – Komissarov et al. 279 (22): 23007


In the present study, the S338C mutant variant of PAI-1 with NBD **group** attached to the **sulphhydryl group** of cysteine (NBD P9 PAI-1) has been used to examine ...
www.jbc.org/cgi/content/full/279/22/23007 - [Similar pages](#)

Carbenoxolone Induces Oxidative Stress in Liver Mitochondria ...

The protein **sulphhydryl group** oxidation assay was performed as in Santos et al. (18). ... Pyridine nucleotide (A) and **sulphhydryl group** (B) oxidation in the ...
endo.endojournals.org/cgi/content/full/146/5/2306 - [Similar pages](#)

Gooooooooogle ►

Result Page: 1 2 3 4 5 6 7 8 9 10 [Next](#)



Google Desktop Search

9:30 AM

Free! Instantly find your email, files, media and web history. [Download now.](#)

[Search within results](#) | [Language Tools](#) | [Search Tips](#) | [Dissatisfied? Help us improve](#)

[Google Home](#) - [Advertising Programs](#) - [Business Solutions](#) - [About Google](#)

©2005 Google

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) Anavist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:05:25 ON 17 DEC 2005

FILE 'MEDLINE' ENTERED AT 07:06:05 ON 17 DEC 2005

FILE 'USPATFULL' ENTERED AT 07:06:05 ON 17 DEC 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 07:06:05 ON 17 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'DGENE' ENTERED AT 07:06:05 ON 17 DEC 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 07:06:05 ON 17 DEC 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 07:06:05 ON 17 DEC 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'BIOSIS' ENTERED AT 07:06:05 ON 17 DEC 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHD5' ENTERED AT 07:06:05 ON 17 DEC 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

=> S (PAI-1 and sulphhydryl group)
6 FILES SEARCHED...

L1 105 (PAI-1 AND SULFHYDRYL GROUP)

=> S 11 and (cysteine or methionine substitution)
L2 72 L1 AND (CYSTEINE OR METHIONINE SUBSTITUTION)

```
=> eskrzypczak, j/au  
ESKRZYPCZAK, IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).
```

=> e skrzypczak, j/au

E1	29	SKRZYPczak W F/AU
E2	6	SKRZYPczak WIESLAW F/AU
E3	0	--> SKRZYPczak, J/AU
E4	1	SKRZYPczaka/AU
E5	1	SKRZYPczakJANKUN/AU
E6	49	SKRZYPczakJANKUN E/AU
E7	2	SKRZYPczakow L/AU
E8	1	SKRZYPczakowa ANDELLNAIN WOJTASZEK L M/AU
E9	24	SKRZYPczakowa L/AU
E10	1	SKRZYPczakPIETRASZEK E/AU
E11	15	SKRZYPczNSKI Z/AU
E12	1	SKRZYPczNSKI ZBIGNIEV/AU

=> s el
L3 29 "SKRZYPCKA W F"/AU

=> S e2
L4 6 "SKRZYPCKA WIESLAW F"/AU

=> s l3 and l4
L5 0 L3 AND L4

=> d 14 ti abs ibib tot

L4 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Renin-angiotensin-aldosterone in the perinatal and neonatal period.
AB This article presents the renin-angiotensin-aldosterone system in animals and humans in the perinatal and neonatal period. The renin-angiotensin-aldosterone system plays an integral role in the physiology of normal pregnancy. During pregnancy plasma angiotensin II, plasma renin activity and aldosterone levels increase their activity in the renin-angiotensin-aldosterone system in the newborn of various species.

ACCESSION NUMBER: 2000:76107 BIOSIS
DOCUMENT NUMBER: PREV200000076107
TITLE: Renin-angiotensin-aldosterone in the perinatal and neonatal period.
AUTHOR(S): Ozog, Malgorzata [Reprint author]; Skrzypczak, Wieslaw F.
CORPORATE SOURCE: ul. Chopina 59/5, 71-466, Szczecin, Poland
SOURCE: Medycyna Weterynaryjna, (Nov., 1999) Vol. 55, No. 11, pp. 737-741. print.
CODEN: MDWTAG. ISSN: 0025-8628.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: Polish
ENTRY DATE: Entered STN: 23 Feb 2000
Last Updated on STN: 3 Jan 2002

L4 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Epiphysis, melatonin and biological rhythm.
ACCESSION NUMBER: 1998:475582 BIOSIS
DOCUMENT NUMBER: PREV199800475582
TITLE: Epiphysis, melatonin and biological rhythm.
AUTHOR(S): Skrzypczak, Wieslaw F. [Reprint author]
CORPORATE SOURCE: ul. Ruginińska 35/19, 71-677 Szczecin, Poland
SOURCE: Medycyna Weterynaryjna, (1998) Vol. 54, No. 9, pp. 586-589. print.
CODEN: MDWTAG. ISSN: 0025-8628.
DOCUMENT TYPE: Article
General Review; (Literature Review)
LANGUAGE: Polish
ENTRY DATE: Entered STN: 5 Nov 1998
Last Updated on STN: 5 Nov 1998

L4 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Monthly variations in the pharmacokinetics of antipyrine in calves.
AB In the experiment (on the basis of values of antipyrine (phenazone) pharmacokinetics parameter), biotransformation activity of calves liver during a year was determined. The experiment was carried out on calves aged 28-30 days. Volume of distribution (V-d), half-life (t-0,5) and metabolic clearance (C-A) of antipyrine were from month to month determined. Not significant changes between values of V-d, t-0,5 and C-A in several months were observed. Results of experiment indicated that calves' liver is characterized by the relatively stable biotransformational activity during the whole year.

ACCESSION NUMBER: 1993:452353 BIOSIS
DOCUMENT NUMBER: PREV199396097253
TITLE: Monthly variations in the pharmacokinetics of antipyrine in calves.
AUTHOR(S): Janus, Krzysztof [Reprint author]; Baranow-Baranowski, Stanislaw; Jakubowska, Dorota; Jankowiak, Dorota; Skrzypczak, Wieslaw F.
CORPORATE SOURCE: Dep. Animal Physiology, ul. Doktora Judyma 6, 71-466 Szczecin, Poland

SOURCE: Archivum Veterinarium Polonicum, Vol. 32, No. 3-4, pp. 113-118. 1992 (1993).
ISSN: 1230-5359.

DOCUMENT TYPE: Article
LANGUAGE: English

ENTRY DATE: Entered STN: 5 Oct 1993
Last Updated on STN: 6 Oct 1993

L4 ANSWER 4 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Seasonal variations of antipyrine pharmacokinetics parameters in calves.
AB In the experiment the values of parameters of antipyrine kinetics were defined (V-d - volume of distribution, t-0.5-half-life, C-A-metabolic clearance) in calves in January, April, July and October 1986 and in January and July 1987. Statistically significant increase of distribution volume and increase of hepatic antipyrine clearance were recorded, as well as significant shortening of half-life of this substance in the organism of tested animals in summer 1986 and 1987, compared with the remaining seasons of the year. Antipyrine pharmacokinetics in winter, spring, autumn 1986 and winter 1986/87 did not differ significantly.

ACCESSION NUMBER: 1993:392707 BIOSIS

DOCUMENT NUMBER: PREV199396068007

TITLE: Seasonal variations of antipyrine pharmacokinetics parameters in calves.

AUTHOR(S): Janus, Krzysztof; Baranow-Baranowski, Stanislaw;
Jakubowska, Dorota; Jankowiak, Dorota; **Skrzypczak, Wieslaw F.**

CORPORATE SOURCE: Dep. Anim. Physiol., Fac. Anim. Husbandry, Agric. Univ.,
ul. Doktora Judyyna 6, 71-466 Szczecin, Poland

SOURCE: Archivum Veterinarium Polonicum, (1992) Vol. 32, No. 1-2,
pp. 67-73.

ISSN: 1230-5359.

DOCUMENT TYPE: Article

LANGUAGE: English

ENTRY DATE: Entered STN: 23 Aug 1993

Last Updated on STN: 24 Aug 1993

L4 ANSWER 5 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI Pharmacokinetics of antipyrine in calves during first 35 days of life.
AB The experiment was carried out on 10 bull-calves of black-white breed, aged 2-35 days. The following parameters of antipyrine pharmacokinetics were determined: V-d - volume of distribution, t-0.5 - biological half-life, C-A - metabolic clearance. It has been shown statistically that the volume of antipyrine distribution (expressed in l/kg) was significantly decreasing with age of examined animals. The antipyrine half-life proved to be the longest on the 20th day of calves' life and the shortest on the 10th and 30th day. The maximum values of metabolic clearance of antipyrine were observed in calves aged 10 days and the minimum ones in animals aged 20 days. In the cases of t-0.5 and C-A a tendency of changes of values of these parameters of antipyrine pharmacokinetics in 10 days periods was observed.

ACCESSION NUMBER: 1993:392706 BIOSIS

DOCUMENT NUMBER: PREV199396068006

TITLE: Pharmacokinetics of antipyrine in calves during first 35 days of life.

AUTHOR(S): Janus, Krzysztof; Baranow-Baranowski, Stanislaw;
Jakubowska, Dorota; Jankowiak, Dorota; **Skrzypczak, Wieslaw F.**

CORPORATE SOURCE: Dep. Anim. Physiol., Fac. Anim. Husbandry, Agric. Univ.,
ul. Doktora Judyyna 6, 71-466 Szczecin, Poland

SOURCE: Archivum Veterinarium Polonicum, (1992) Vol. 32, No. 1-2,
pp. 75-81.

ISSN: 1230-5359.

DOCUMENT TYPE: Article

LANGUAGE: English
ENTRY DATE: Entered STN: 23 Aug 1993
Last Updated on STN: 24 Aug 1993

L4 ANSWER 6 OF 6 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
TI The influence of ACTH and hydrocortisone on drug kinetics in calves on the
example of antipyrine test.
AB The aim of the experiment carried out on 2 groups (to comprise 8
specimens) bull calves, of ncb. breed, at the age of 60 to 65 days and of
an average body weight 90 +- 5 kg, was to define the effect of
intramuscular ACTH (0,2j.m. kg b.w.) and hydrocortisone (0,2 mg kg b.w.)
injections on the hepatic biotransformation of antipyrine. No changes
were noticed in the quantity of antipyrine distribution space V-d under
the influence of the hormonal preparations applied. Shorter time of
antipyrine halflife from the body T/2 was observed, yet the differences
stated have not confirmed statistically. ACTH and hydrocortisone
injections caused the increase in constant elimination value of antipyrine
from the organism k as well as the increase in the quantity of hepatic
antipyrine clearance Cl A. The differences observed have not turned out
to be statistically significant.

ACCESSION NUMBER: 1993:99071 BIOSIS

DOCUMENT NUMBER: PREV199395054267

TITLE: The influence of ACTH and hydrocortisone on drug kinetics
in calves on the example of antipyrine test.

AUTHOR(S): Janus, Krzysztof [Reprint author]; Jakubowska, Dorota;
Jankowiak, Dorota; Skrzypczak, Wieslaw F.

CORPORATE SOURCE: ul. Bohaterow Stalingradu 7/4, 74-100 Gryfino,

SOURCE: Polskie Archiwum Weterynaryjne, (1991) Vol. 31, No. 1-2,
pp. 25-31.

CODEN: PARWAC. ISSN: 0079-3647.

DOCUMENT TYPE: Article

LANGUAGE: Polish

ENTRY DATE: Entered STN: 9 Feb 1993

Last Updated on STN: 10 Feb 1993

=> d his

(FILE 'HOME' ENTERED AT 07:05:25 ON 17 DEC 2005)

FILE 'MEDLINE, USPATFULL, SCISEARCH, DGENE, EMBASE, WPIDS, BIOSIS,
BIOTECHDS' ENTERED AT 07:06:05 ON 17 DEC 2005

L1 105 S (PAI-1 AND SULFHYDRYL GROUP)

L2 72 S L1 AND (CYSTEINE OR METHIONINE SUBSTITUTION)
E SKRZYPczAK, J/AU

L3 29 S E1

L4 6 S E2

L5 0 S L3 AND L4

=> s l3 and l1

L6 0 L3 AND L1

=> e skrzypczak-wynimko, j/au

E1 29 SKRZYPczAK W F/AU

E2 6 SKRZYPczAK WIESLAW F/AU

E3 0 --> SKRZYPczAK-WYNIMKO, J/AU

E4 1 SKRZYPczAKA/AU

E5 1 SKRZYPczAKJANKUN/AU

E6 49 SKRZYPczAKJANKUN E/AU

E7 2 SKRZYPczAKOW L/AU

E8 1 SKRZYPczAKOWA ANDELLNAIN WOJTASZEK L M/AU

E9 24 SKRZYPczAKOWA L/AU

E10 1 SKRZYPczAKPIETRASZEK E/AU

E11 15 SKRZYP CZNSKI Z/AU
E12 1 SKRZYP CZNSKI ZBIGNIEV/AU

=> d his

(FILE 'HOME' ENTERED AT 07:05:25 ON 17 DEC 2005)

FILE 'MEDLINE, USPATFULL, SCISEARCH, DGENE, EMBASE, WPIDS, BIOSIS,
BIOTECHDS' ENTERED AT 07:06:05 ON 17 DEC 2005

L1 105 S (PAI-1 AND SULFHYDRYL GROUP)
L2 72 S L1 AND (CYSTEINE OR METHIONINE SUBSTITUTION)
E SKRZYP CZAK, J/AU
L3 29 S E1
L4 6 S E2
L5 0 S L3 AND L4
L6 0 S L3 AND L1
E SKRZYP CZAK-WYNIMKO, J/AU

=> d 12 ti abs ibib 1-20

L2 ANSWER 1 OF 72 USPATFULL on STN

TI Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof

AB Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof are provided. The antibodies and antibody conjugates, which may include a therapeutic agent or a diagnostic agent, may be used to treat, prevent or detect diseases such as for example cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:267608 USPATFULL

TITLE: Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof

INVENTOR(S): Mazar, Andrew P., San Diego, CA, UNITED STATES
Ternansky, Robert J., San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Gawlak, Susan, Hamden, CT, UNITED STATES

PATENT ASSIGNEE(S): Attenuon LLC (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2005232924 A1 20051020

APPLICATION INFO.: US 2004-993007 A1 20041118 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2003-523255P 20031118 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Sunil K. Singh, Dorsey & Whitney LLP, Intellectual Property Department, Four Embarcadero Center, Suite 3400, San Francisco, CA, 94111-4187, US

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 2282

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 72 USPATFULL on STN

TI Method for preparing modified polypeptides

AB Methods for producing polypeptide with altered immunogenicity or

improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:255891 USPATFULL
TITLE: Method for preparing modified polypeptides
INVENTOR(S): Halkier, Torben, Solroed Strand, DENMARK
Pedersen, Anders Hjelholt, Lyngby, DENMARK
Okkels, Jens Sigurd, Vedbaek, DENMARK
Anderson, Kim Vilbour, Copenhagen, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005222389	A1	20051006
APPLICATION INFO.:	US 2004-756813	A1	20040112 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-389283, filed on 14 Mar 2003, ABANDONED Continuation of Ser. No. US 2002-190414, filed on 3 Jul 2002, ABANDONED Continuation of Ser. No. US 2000-611234, filed on 6 Jul 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1999-988	19990707
	DK 1999-1196	19990827
	DK 2000-339	20000302
	DK 2000-804	20000518
	US 1999-160693P	19991021 (60)
	US 2000-189503P	20000315 (60)
	US 2000-207793P	20000530 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MAXYGEN, INC., INTELLECTUAL PROPERTY DEPARTMENT, 515 GALVESTON DRIVE, RED WOOD CITY, CA, 94063, US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 3150
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 3 OF 72 USPATFULL on STN

TI Poxvirus with targeted infection specificity

AB The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:240074 USPATFULL
TITLE: Poxvirus with targeted infection specificity
INVENTOR(S): Balloul, Jean Marc, Lingolsheim, FRANCE
Paul, Stephane, Strasbourg, FRANCE
Geist, Michel, Brumath, FRANCE
Silvestre, Nathalie, Ergersheim, FRANCE
Erbs, Philippe, Strasbourg, FRANCE
PATENT ASSIGNEE(S): TRANSGENE S.A., Strasbourg, FRANCE, 67000 (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005208074	A1	20050922
APPLICATION INFO.:	US 2004-934728	A1	20040907 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-832899, filed on 12 Apr 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-440109	20000414
	EP 2001-440009	20010122
	US 2000-246080P	20001107 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BUCHANAN INGERSOLL PC, (INCLUDING BURNS, DOANE, SWECKER & MATHIS), POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404, US	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	3649	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 72 USPATFULL on STN
TI Use of p97 as an enzyme delivery system for the delivery of therapeutic
lysosomal enzymes
AB The present invention provides for compositions and methods for
treating, ameliorating or preventing a lysosomal storage disease by
administering to a patient suffering from a lysosomal storage disease a
P97 conjugated with an enzyme which is capable of transportation into
the lysosomes of cells on either sides of the blood brain barrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:182913 USPATFULL
TITLE: Use of p97 as an enzyme delivery system for the
delivery of therapeutic lysosomal enzymes
INVENTOR(S): Starr, Christopher M., Sonoma, CA, UNITED STATES
Zankel, Todd, Novato, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158296	A1	20050721
APPLICATION INFO.:	US 2003-501028	A1	20030110 (10)
	WO 2003-US894		20030110
PRIORITY INFORMATION:	US 2003-347758P		20020111 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MARSHALL, GERSTEIN & BORUN LLP, 233 S. WACKER DRIVE, SUITE 6300, SEARS TOWER, CHICAGO, IL, 60606, US		

NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1880
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 72 USPATFULL on STN

TI Modified plasminogen inhibitor type-1 and methods based thereon
AB The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (**PAI-1**) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a **sulfhydryl group** and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified **PAI-1** proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified **PAI-1**, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:182912 USPATFULL
TITLE: Modified plasminogen inhibitor type-1 and methods based thereon
INVENTOR(S): Swiercz, Rafal, Bastrop, TX, UNITED STATES
Selman, Steven H., Toledo, OH, UNITED STATES
Jankun, Jerzy, Sylvania, OH, UNITED STATES
Skrzypczak-Jankun, Ewa, Sylvania, OH, UNITED STATES
Chorostowska-Wynimko, Joanna, Warsaw, POLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005158295	A1	20050721
APPLICATION INFO.:	US 2003-506406	A1	20030304 (10)
	WO 2003-US6679		20030304

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-361670P	20020304 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	3399	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 6 OF 72 USPATFULL on STN

TI Cancer treatment methods using selected antibodies to aminophospholipids
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based

compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:157851 USPATFULL

TITLE: Cancer treatment methods using selected antibodies to aminophospholipids

INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2005136059 A1 20050623

APPLICATION INFO.: US 2003-642071 A1 20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION: US 2002-396263P 20020715 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 53 Drawing Page(s)

LINE COUNT: 13044

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 7 OF 72 USPATFULL on STN

TI Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:150785 USPATFULL

TITLE: Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2005129696 A1 20050616

APPLICATION INFO.: US 2003-642065 A1 20030815 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION: US 2002-396263P 20020715 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE

1100, HOUSTON, TX, 77042, US
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13046
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 8 OF 72 USPATFULL on STN
TI Cell surface tropomyosin as a target of angiogenesis inhibition
AB The present invention is directed to novel methods for inhibiting angiogenesis and treating tumors and cancer by targeting tropomyosin (Tpm) expressed on the surface of endothelial cells and/or tumor cells, to Tpm polypeptides and peptides, as well as variants and derivatives thereof that bind inhibitors of angiogenesis, and to anti-Tpm antibodies that block or stimulate angiogenesis. Cyclic peptides that bind to the D5 subunit of HK.sub.a and inhibit angiogenesis are also included. Method for screening test compounds as candidate antiangiogenic molecule that binds to Tpm are disclosed, as are affinity ligands comprising the proteins, peptides, variants and derivatives of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:145053 USPATFULL
TITLE: Cell surface tropomyosin as a target of angiogenesis inhibition
INVENTOR(S): McCrae, Keith, Pepper Pike, OH, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Juarez, Jose, San Diego, CA, UNITED STATES
Mazar, Andrew P., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005124794	A1	20050609
APPLICATION INFO.:	US 2003-507734	A1	20030317 (10)
	WO 2003-US8060		20030317

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-364047P	20020315 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MCKENNA LONG & ALDRIDGE LLP, 1900 K STREET, NW, WASHINGTON, DC, 20006, US	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	4919	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 9 OF 72 USPATFULL on STN
TI Antibody conjugate methods for selectively inhibiting VEGF
AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:143802 USPATFULL
TITLE: Antibody conjugate methods for selectively inhibiting VEGF
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES

PATENT ASSIGNEE(S) : Brekken, Rolf A., Seattle, WA, UNITED STATES
Board of Regents, The University of Texas System (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005123537	A1	20050609
APPLICATION INFO.:	US 2003-738404	A1	20031217 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-561005, filed on 28 Apr 2000, GRANTED, Pat. No. US 6703020		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Shelley P.M. Fussey, Ph.D., WILLIAMS, MORGAN & AMERSON, P.C., 10333 Richmond, Suite 1100, Houston, TX, 77042, US	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1-2	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	10237	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 10 OF 72 USPATFULL on STN

TI Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases

AB This invention pertains to methods for imaging the activity of extracellular proteases in cells using the anthrax binary toxin-system to target cells expressing extracellular proteases with mutant anthrax toxin protective antigens (μ PrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the cells, and ligands that specifically bind to the cleaved μ PrAg and are linked to a moiety that is detectable by an imaging procedure. The μ PrAg proteins used in the methods comprise a protease cleavage site that is cleaved by a specific extracellular protease and is in place of the furin cleavage site of the native PrAg. The methods are useful for diagnosing and treating diseases and undesirable physiological conditions correlated with the activity of extracellular proteases, and for optimizing the therapeutic efficacy of drugs used to treat such diseases and conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:143741 USPATFULL

TITLE: Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases

INVENTOR(S) : Bugge, Thomas H., Bethesda, MD, UNITED STATES
Leppla, Stephen H., Bethesda, MD, UNITED STATES
Liu, Shi-Hui, Rockville, MD, UNITED STATES
Mitola, David, Baltimore, MD, UNITED STATES

PATENT ASSIGNEE(S) : The Government of the United States as represented by the Secretary of the Department of Health and, Rockville, MD, UNITED STATES, 20852-3804 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005123476	A1	20050609
APPLICATION INFO.:	US 2003-488806	A1	20020905 (10)
	WO 2002-US28397		20020905

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-317550P	20010905 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 94111, US	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4268	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 11 OF 72 USPATFULL on STN
 TI Antibody kits for selectively inhibiting VEGF
 AB Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2005:107236 USPATFULL
 TITLE: Antibody kits for selectively inhibiting VEGF
 INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
 Brekken, Rolf A., Seattle, WA, UNITED STATES
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,
 Austin, TX, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6887468	B1	20050503
APPLICATION INFO.:	US 2000-562245		20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-131432P	19990428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Nickol, G.	
ASSISTANT EXAMINER:	Yaen, C.	
LEGAL REPRESENTATIVE:	Williams, Morgan and Amerson	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	10510	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 12 OF 72 USPATFULL on STN
 TI Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids
 AB Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood

vessels, thereby inducing thrombosis, necrosis and tumor regression.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:104590 USPATFULL
TITLE: Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Ran, Sophia, Dallas, TX, UNITED STATES
Brekken, Rolf A., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005089523	A1	20050428
APPLICATION INFO.:	US 2004-988245	A1	20041112 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-351598, filed on 12 Jul 1999, GRANTED, Pat. No. US 6818213		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92589P	19980713 (60)
	US 1998-110600P	19981202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1-63	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	8230	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 13 OF 72 USPATFULL on STN
TI Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:69437 USPATFULL
TITLE: Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Soares, M. Melina, Richardson, TX, UNITED STATES
He, Jin, Dallas, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005059578	A1	20050317
APPLICATION INFO.:	US 2003-642121	A1	20030815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 53 Drawing Page(s)
LINE COUNT: 13308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 14 OF 72 USPATFULL on STN
TI Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
AB Human kininogen domain 3 (HK-D3) polypeptides and biologically active variants and derivatives of HK-D3 are anti-angiogenic. These molecules are used to inhibit angiogenesis or treat a disease or condition in which angiogenesis is pathogenic. Because of their anti-angiogenic potential, these molecules are useful in the treatment of cancer by inhibiting or reversing the growth of primary or metastatic tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:68461 USPATFULL
TITLE: Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
INVENTOR(S): Donate, Fernando, San Diego, CA, UNITED STATES
Mazar, Andrew P., San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005058599	A1	20050317
APPLICATION INFO.:	US 2003-661784	A1	20030915 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP, P.O. BOX 34385, WASHINGTON, DC, 20043-9998		
NUMBER OF CLAIMS:	42		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	2615		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 72 USPATFULL on STN
TI Megalin-based delivery of therapeutic compounds to the brain and other tissues
AB The present invention is directed to methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:49435 USPATFULL
TITLE: Megalin-based delivery of therapeutic compounds to the brain and other tissues
INVENTOR(S): Zankel, Todd, San Francisco, CA, UNITED STATES
Starr, Christopher M., Sonoma, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005042227	A1	20050224
APPLICATION INFO.:	US 2004-812849	A1	20040330 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-600862, filed on 20 Jun 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		

LEGAL REPRESENTATIVE: MARSHALL, GERSTEIN & BORUN LLP, 6300 SEARS TOWER, 233 S. WACKER DRIVE, CHICAGO, IL, 60606
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 37 Drawing Page(s)
LINE COUNT: 5434
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 16 OF 72 USPATFULL on STN
TI Combined cancer treatment methods using selected antibodies to aminophospholipids
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:36945 USPATFULL
TITLE: Combined cancer treatment methods using selected antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005031620	A1	20050210
APPLICATION INFO.:	US 2003-642058	A1	20030815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	53 Drawing Page(s)	
LINE COUNT:	13439	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 17 OF 72 USPATFULL on STN
TI Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AB This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:31386 USPATFULL
TITLE: Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues

INVENTOR(S) : Zankel, Todd, San Francisco, CA, UNITED STATES
Starr, Christopher M., Sonoma, CA, UNITED STATES
Gabathuler, Reinhart, San Rafael, CA, UNITED STATES
PATENT ASSIGNEE(S) : BioMarin Pharmaceutical Inc., Novato, CA (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005026823	A1	20050203
APPLICATION INFO.:	US 2003-600862	A1	20030620 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Nabeela R. McMillian, MARSHALL, GERSTEIN & BORUN LLP, Sears Tower, 233 S. Wacker Drive, Suite 6300, Chicago, IL, 60606-6357		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	20 Drawing Page(s)		
LINE COUNT:	4151		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

L2 ANSWER 18 OF 72 USPATFULL on STN
TI Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2005:30331 USPATFULL
TITLE: Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
INVENTOR(S) : Thorpe, Philip E., Dallas, TX, UNITED STATES
Soares, M. Melina, Richardson, TX, UNITED STATES
He, Jin, Dallas, TX, UNITED STATES
PATENT ASSIGNEE(S) : Board of Regents, The University of Texas System (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005025761	A1	20050203
APPLICATION INFO.:	US 2003-642100	A1	20030815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	52 Drawing Page(s)	
LINE COUNT:	13426	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L2 ANSWER 19 OF 72 USPATFULL on STN
TI Peptides which target tumor and endothelial cells, compositions and uses thereof
AB The present invention relates generally to peptide analogs of Ac--PHSCN--NH₂.2 which target tumor and endothelial cells and have anti-tumor, anti-angiogenic and anti-metastatic activity, methods of making these peptides, compositions thereof and methods of using these peptides and pharmaceutical compositions thereof to treat, prevent and detect diseases characterized by tumor growth, metastasis and angiogenesis. The peptide analogs may serve, inter alia, as carriers of radioactivity, PET-active compounds, toxins, fluorescent molecules and PEG molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:24260 USPATFULL
TITLE: Peptides which target tumor and endothelial cells, compositions and uses thereof
INVENTOR(S): Ternansky, Robert J., San Diego, CA, UNITED STATES
Allan, Amy L., Encinitas, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005020810	A1	20050127
APPLICATION INFO.:	US 2003-722843	A1	20031125 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-429174P	20021125 (60)
	US 2003-475539P	20030602 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Sunil K. Singh, Dorsey & Whitney LLP, Intellectual Property Department, Four Embarcadero Center, Suite 3400, San Francisco, CA, 94111-4187	
NUMBER OF CLAIMS:	74	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3884	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 72 USPATFULL on STN
TI Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
AB Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:3839 USPATFULL
TITLE: Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
INVENTOR(S): Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES

PATENT ASSIGNEE(S) : Ran, Sophia, Riverton, IL, UNITED STATES
Board of Regents, The University of Texas System (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005002941	A1	20050106
APPLICATION INFO.:	US 2003-642116	A1	20030815 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-396263P	20020715 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WILLIAMS, MORGAN & AMERSON, P.C., 10333 RICHMOND, SUITE 1100, HOUSTON, TX, 77042	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	53 Drawing Page(s)	
LINE COUNT:	13468	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		